Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres








Gamme d'année
1.
Indian J Pediatr ; 2003 Jun; 70(6): 485-8
Article de Anglais | IMSEAR | ID: sea-84128

RÉSUMÉ

Pertussis still continues to cause significant morbidity and mortality worldwide. Because of the high reactogenicity of whole cell pertussis vaccine, it had evoked public controversy in several countries. In 1970 Japan abandoned use of whole cell pertussis vaccine and mounted efforts to develop better vaccine. To date, nearly 24 acellular pertussis vaccines have been developed, using different number and quantity of components. No acellular vaccine is most or least immunogenic with respect to all included antigens. Vaccine efficacy and duration of immunity is comparable with whole cell pertussis vaccine. The adverse events are two thirds less compared to whole cell vaccine.


Sujet(s)
Essais cliniques comme sujet , Analyse coût-bénéfice , Vaccin diphtérie-tétanos-coqueluche/administration et posologie , Vaccins diphtérique tétanique coquelucheux acellulaires/administration et posologie , Association de médicaments , Humains , Calendrier vaccinal , Vaccin anticoquelucheux/administration et posologie , Coqueluche/économie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE